Skip to main content
. Author manuscript; available in PMC: 2024 Nov 29.
Published in final edited form as: Mol Pharm. 2023 Aug 8;20(9):4629–4639. doi: 10.1021/acs.molpharmaceut.3c00360

Figure 5.

Figure 5.

PET/CT images at 24, 48, and 72 h postinjection of a HER2-negative tumor-bearing mouse (SUVmean scale 0.3–2). No PET signal could be visualized in the tumor at the selected window to compare with the HER2-positive mice. The tumor is located on the left shoulder in the same area as the HER2-positive tumor-bearing mice.